GE HealthCare Technologies Inc

GE Healthcare Technologies, Inc. operates as a holding company with interest in providing medical technology, pharmaceutical diagnostics and digital solutions. Its operating segments include Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded on May 16, 2022 and is headquartered in Chicago, IL.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GE HealthCare posts robust Q4 results, eyes growth opportunities

GE HealthCare Technologies Inc delivered a strong Q4 2022 performance with notable organic revenue growth and margin expansion.
While facing challenges such as COVID-related impacts and debt interest, the company is well-positioned for growth through pricing strategies and market demand.
Opportunities lie in continued revenue growth, margin expansion, and product innovations, supported by strong market demand and strategic initiatives.
Overall, GE HealthCare's focus on performance improvement, innovation, and financial discipline sets a positive trajectory for future growth and competitiveness.

GE HealthCare reports robust Q1 earnings, eyes growth opportunities

GE HealthCare Technologies Inc delivered strong financial results in Q1 2023, with revenue growth, margin improvement, and reaffirmed guidance for the full year. The company's focus on innovation, technology investments, and strategic acquisitions positions it well for future growth.

GE HealthCare reports strong Q2 earnings, eyes precision care growth

GE HealthCare Technologies delivered strong financial performance in Q2 2023, driven by revenue growth, innovation in AI technologies, and strategic investments in key segments.
While facing challenges such as margin improvements and geopolitical risks, the company remains focused on capitalizing on growth opportunities in precision care and technological advancements.
Executives emphasized a balanced approach to capital allocation, margin expansion, and long-term growth strategies, positioning GEHC for sustained success in the evolving healthcare landscape.
Overall, GEHC's Q2 earnings call highlighted a resilient business outlook, with a clear focus on driving innovation, enhancing margins, and seizing opportunities for growth and market leadership.

GE HealthCare reports solid Q3 growth, eyes opportunities amid challenges

GE HealthCare Technologies Inc reported strong Q3 2023 performance with revenue growth, margin expansion, and strategic collaborations.
The company faces challenges in capital spending sentiment, margin targets, and managing balance sheet risks.
Opportunities for growth include new product launches, market focus, and upcoming investor engagements.
Overall, GEHC's resilience, operational improvements, and growth strategies position it well for future success.

GE HealthCare reports robust earnings, eyes growth through innovation

GE HealthCare Technologies Inc delivered strong financial performance in Q4 2023 and full-year 2023, driven by organic growth, strategic acquisitions, and margin expansion initiatives.
While facing challenges such as anticipated market declines and macroeconomic uncertainties, the company is well-positioned to leverage opportunities in increased demand, innovative technologies, and strategic partnerships.
By focusing on driving value through innovation, sustainability, and strategic investments, GE HealthCare is poised for continued growth and market leadership in the healthcare technology sector.
The outlook for 2024 indicates a positive trajectory with anticipated revenue growth, margin expansion, and a commitment to delivering high-value solutions to customers, supported by a strong financial foundation.

GE Healthcare reports steady Q1 performance amidst global challenges

GE Healthcare Technologies showcased a mixed performance in Q1 2024, with flat organic revenue growth and varied segment results.
The company remains focused on strategic alliances, margin initiatives, and cost savings to support EBIT expansion and solid margin performance.
Challenges in China sales and the need for clarity on the stimulus package present uncertainties, while opportunities lie in segment growth and new product introductions.

GE HealthCare reports steady Q2 growth amidst China challenges

GE HealthCare Technologies Inc delivered solid Q2 performance with growth in key segments like Patient Care Solutions and Pharmaceutical Diagnostics. Despite challenges in China, the company remains focused on driving margin expansion and innovation for sustained growth.

GE HealthCare reports steady Q3 growth amidst China market challenges

GE HealthCare Technologies Inc delivered a solid financial performance in Q3 2024, with 1% organic revenue growth and strong margin performance.
While facing challenges in the slow recovery of the China market, the company showcased strengths in free cash flow generation and technological innovations.
Future opportunities lie in margin expansion, growth initiatives like Flyrcado and AI solutions, and market differentiation through innovative healthcare technologies.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment provides scanning devices, clinical applications, service capabilities and digital solutions. The Ultrasound segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The Patient Care Solutions segment specializes in providing medical devices, consumables, services, and digital solutions. The Pharmaceutical Diagnostics segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company’s history roots back to the year 1892 and it was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GE HealthCare (GEHC) is expected to report strong organic revenue growth, banking on balanced segmental performance driven by consistent NPIs and growing customer demand.

GE HealthCare (GEHC) to Report Q3 Earnings: What's in Store?

Novo Nordisk

GE HealthCare Technologies Inc. GEHC, -2.35% on Thursday said it is teaming up with Novo Nordisk NVO, -0.58% to develop an ultrasound treatment for type 2 diabetes and obesity.

GE HealthCare teams up with Novo Nordisk to treat diabetes without drugs

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced a collaboration with Novo Nordisk to further advance the clinical and product development of peripheral focused ultrasound (PFUS). This is a novel technology that has potential to specifically regulate metabolic function in the body using ultrasound that may support the treatment of chronic diseases such as type 2 diabetes and obesity. PFUS is a non-invasive type of bioelectronic medicine that uses ultrasound to activate the.

GE HealthCare and Novo Nordisk to Collaborate to Advance Novel Non-Invasive Treatment for Type 2 Diabetes and Obesity with Ultrasound

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), a leader in precision care innovation, will announce its third quarter 2023 financial results before the market opens on Tuesday, October 31, 2023. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast r.

GE HealthCare to Announce Third Quarter 2023 Results on October 31, 2023

CHICAGO--(BUSINESS WIRE)--Today, GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest addition to the company's image guided system (IGS) offerings. Allia IGS Pulse features a new imaging chain engineered to provide exceptional imaging at the right dose for visible impact in complex cardiology interventions regardless of patient size. In modern healthcare today, cardiovascular disease (CVD) continues to grow in prevalence, with CVDs being the leading ca.

GE HealthCare Receives FDA Clearance of Allia IGS Pulse - the Next Generation of Image-Guided Systems Designed for Cardiac Imaging Excellence

SAN FRANCISCO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced new data from a pilot study conducted with Cleveland Clinic evaluating the Portrait Mobile wireless and wearable monitoring solution. The results demonstrate that continuous patient monitoring with Portrait Mobile resulted in alarm data suitable for optimization of ward default values and further refinement on an individual basis seems likely to improve usability. The data was presented during the ASA 2023 Annual Meeti.

GE HealthCare Announces Study Results Demonstrating Portrait Mobile Continuous Monitoring Solution Performance with Patients and Care Teams in the Ward

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it signed a $44 million contract with the Biomedical Advanced Research and Development Authority (BARDA)—part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS)—to develop and obtain regulatory clearance for next-generation advanced point-of-care ultrasound technology with new artificial intelligence (AI) applications. Technology resulting from t.

GE HealthCare Signs $44 Million Contract with BARDA to Develop Artificial Intelligence-Augmented Ultrasound Technology to Aid Clinicians in Diagnosing and Treating Traumatic Injury and Enhance National Preparedness for Mass Casualty Incidents

CHALFONT ST GILES, England--(BUSINESS WIRE)--SOFIE Biosciences and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers.

SOFIE and GE HealthCare Enter Licensing Agreement to Develop FAP PET Radiotracers

WAUKESHA, Wis.--(BUSINESS WIRE)--As part of a research study, researchers at Stanford Medicine, Department of Radiology recently began scanning human subjects on GE HealthCare's novel photon counting CT prototype designed with Deep Silicon detectors,i,ii which aims to greatly enhance imaging capabilities and provide clinicians the information and data they need to help enable improved patient outcomes across oncology, cardiology, neurology, and other clinical CT applications. Photon counting CT.

GE HealthCare's growing list of medical institutions conducting human subject research studies with its novel photon counting CTi technology further expands with the addition of Stanford Medicine

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced its Venue Family point-of-care ultrasound systems will now feature Caption Guidance, artificial intelligence (AI)-driven technology that provides real-time guidance to users for capturing diagnostic-quality cardiac images. The Venue Family is the first among GE HealthCare ultrasound products to incorporate this scan guidance technology following the company's acquisition of Caption Health earlier this year. Caption Guidance.

GE HealthCare Launches Enhanced Venue Family Point-of-Care Ultrasound Systems Featuring AI-Driven Caption Guidance

CHICAGO--(BUSINESS WIRE)--Realizing a vision to deliver the best care to patients close to where they live in northern Ohio, GE HealthCare and University Hospitals (UH) today announced a 10-year strategic collaboration to bring GE HealthCare technologies to UH across its radiology practice and UH Harrington Heart & Vascular Institute, providing contemporary equipment and digital solutions to improve processes for the benefit of patients and clinicians. The agreement includes hundreds of new.

GE HealthCare and University Hospitals Enter 10-Year Strategic Collaboration to Contemporize Its Imaging Fleet and Implement Enterprise Digital Solutions to Help Improve Patient Care and Optimize Processes

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC), a leading medical technology, pharmaceutical diagnostics, and digital solutions innovator, today declared a cash dividend of $0.03 per share of Common Stock for the third quarter of 2023 payable on November 15, 2023 to all shareholders of record as of October 20, 2023. About GE HealthCare GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innov.

GE HealthCare Announces Cash Dividend for Third Quarter of 2023

Privia Health Group

Investors with an interest in Medical Info Systems stocks have likely encountered both GE HealthCare Technologies (GEHC) and Privia Health (PRVA). But which of these two stocks is more attractive to value investors?

GEHC or PRVA: Which Is the Better Value Stock Right Now?

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today released its inaugural Sustainability Report, which describes the steps the Company has taken to establish its stand-alone environmental, social, and governance (ESG) practice and infrastructure, as well as how it has bolstered the foundation put in place prior to its spin-off from GE. The report incorporates findings from GE HealthCare's existing ESG materiality assessment, which informed the Company's ESG strategy, and outlines the.

GE HealthCare Shares Key Focus Areas and Future Goals in its Inaugural Sustainability Report

GEHC was spun off from GE almost a year ago, and its stock price is almost back to where it started. The company has great revenue prospects and an opportunity to expand margins and improve profitability. It is trading at depressed multiples compared to its peers, and we think it can compound money at a 22% CAGR over the next three years.

GE Healthcare: Revenue Growth, Margin Expansion And Attractive Valuation

Citi analyst Joanne Wuensch launched coverage of GE HealthCare Technologies stock with a Buy rating and $82 price target.

GE HealthCare Stock Is Too Cheap, Says Analyst

GE HealthCare Technologies Inc has received a grant of more than $44 million from the Bill & Melinda Gates Foundation to develop AI-assisted ultrasound technology, the company said on Monday.

GE HealthCare gets $44 mln grant to develop AI-assisted ultrasound tech

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced it received a grant from the Bill & Melinda Gates Foundation for more than $44 million to create user-friendly, artificial intelligence (AI)-assisted ultrasound imaging auto-assessment tools. These tools will seek to aid healthcare professionals—even those without specialized training or experience with ultrasound—with clinical decision information to support more effective obstetric and lung screening ultrasound scans a.

GE HealthCare Awarded a $44 Million Grant to Develop Artificial Intelligence-Assisted Ultrasound Technology Aimed at Improving Outcomes in Low-and-Middle-Income Countries

ROCHESTER, Minn.--(BUSINESS WIRE)--Today, Mayo Clinic and GE HealthCare announce a strategic healthcare collaboration for research and product development programs aimed to transform the experience of patients and clinicians in the practice of radiology and the delivery of novel therapies. The Strategic Collaboration for Innovation in Medical Imaging and Theranostics comprises Mayo Clinic and GE HealthCare scientists, technology developers, clinicians and other healthcare providers. The collabo.

Mayo Clinic and GE HealthCare Enter Strategic Collaboration to Advance Innovation in Medical Imaging and Theranostics

On July 25, 2023, GE HealthCare Technologies, one of the leading companies in developing and commercializing medical devices and pharmaceutical diagnostics, published financial results for the second quarter of 2023. GE HealthCare's revenue amounted to $4.82 billion for the quarter, 2.3% more than the previous quarter and 7.6% more than the second quarter of 2022. As a result, GE HealthCare management raised its full-year 2023 guidance for adjusted EPS from $3.60-$3.75 to $3.70-$3.85.

Why Did GE HealthCare Excel Beyond The COVID-19 Crisis?

ExScientia Ltd

Intuitive Surgical

Med tech stocks are ripe for growth due to the advent of artificial intelligence ( AI ). AI is going to improve healthcare overall.

3 Med Tech Stocks That the AI Boom Will Only Help

CHICAGO--(BUSINESS WIRE)--GE HealthCare and Mass General Brigham announced, as part of its initial collaboration, the co-development of an artificial intelligence (AI) algorithm that will help increase operations effectiveness and productivity. The first innovative AI application from the collaboration is the schedule predictions dashboard of Radiology Operations Module (ROM), a digital imaging tool that helps optimize scheduling, reduce cost, and free providers from administrative burden, allo.

GE HealthCare and Mass General Brigham Collaborate on an AI Algorithm to Predict Missed Care Opportunities

Allegion

Johnson Controls

A healthcare technology company with revenue growth and margin expansion opportunities. A building controls company with exposure to the corporate drive towards net zero emissions.

Got $2,000? Here Are 3 Smart Stocks To Buy Now

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the launch of Vscan Air SL – a handheld, wireless ultrasound imaging system designed for rapid cardiac and vascular assessments at the point of care to help clinicians accelerate diagnoses and treatment decisions. The latest addition to the Vscan product suite, Vscan Air SL features GE HealthCare's proprietary SignalMax and XDclear technology that provide high levels of penetration, resolution, and sensitivity in imaging per.

GE HealthCare Introduces Vscan Air SL, a Wireless Handheld Ultrasound Device for Rapid Assessments of Cardiac and Vascular Patients

CHICAGO--(BUSINESS WIRE)--Today, GE HealthCare (Nasdaq: GEHC) announces the launch of CardioVisio for Atrial Fibrillation (AFib), a digital tool designed to assist clinicians in visualizing longitudinal data relevant for disease progression from multiple data sources, and driving evidence based clinical decision support directed by up-to-date AFib guidelines. The new technology will be showcased at the European Society of Cardiology (ESC) Congress 2023, in Amsterdam, Netherlands, August 25-28.

News for GE HealthCare Technologies Inc Stock (GEHC)